Aktuelle smitsomme sygdomme
Søgeord (hiv) valgt.
6 emner vises.
Julien Beauté and Francesco Innocenti
Eurosurveillance latest updates, 17.08.2024
Tilføjet 17.08.2024
Background There are differences between males and females for most diseases both for exposure and course of illness, including outcome. These differences can be related to biological sex or gender i.e. socio-cultural factors that may impact exposure and healthcare access. Aim We aimed to quantify differences between males and females in infectious disease notifications in Europe and identify countries with these differences significantly different from the European Union and European Economic Area (EU/EEA) average. Methods Notifiable infectious disease surveillance data are reported by EU/EEA countries to ECDC. We retrieved surveillance data for 2012−2021. Using a cut-off median of annual disability-adjusted life years above 1 per 100,000 population, we included 16 infectious diseases. We calculated median male proportion and interquartile range by disease, year, country and age group and used boxplots to identify outliers. Results For campylobacteriosis, acute hepatitis B, Legionnaires’ disease, malaria and HIV and AIDS, all countries had male proportion above 50%. Most countries had a male proportion below 50% for pertussis (25/28 countries), STEC infection (21/28 countries) and Chlamydia trachomatis infection (16/24 countries). Chlamydia trachomatis infection and listeriosis showed the greatest dispersion of male proportion across age groups. Most outliers were countries reporting few cases. Conclusion We observed important differences in male proportion across infectious disease notifications in EU/EEA countries. For some diseases with high male proportions in all countries, such as HIV and hepatitis B, behaviours play a role in disease transmission. Screening offered to specific populations may explain differences across countries for example for C. trachomatis infection.
Læs mereMedscape Infectious Diseases, 29.07.2024
Tilføjet 29.07.2024
The newest stem cell recipient to test negative for HIV after cancer treatment had a donor with a single — rather than double — gene mutation that is opening the donor pool in renewed cure efforts. Medscape Medical News
Læs merePablo Ryan, Samuel Manzano, Neda Deihim-Rahampour, Guillermo Cuevas, Laura Martin-Gonzalez, Alicia Gonzalez-Baeza, Pedro Torres, Jeffrey V Lazarus, Juan Torres-Macho, Jorge Valencia and Matilde Sanchez-Conde
Eurosurveillance latest updates, 20.07.2024
Tilføjet 20.07.2024
BackgroundRecent migration trends have shown a notable entry of Latin American asylum seekers to Madrid, Spain. AimTo characterise the profile of asylum-seeking Latin American migrants who are living with HIV in Spain and to outline the barriers they face in accessing HIV treatment. MethodsA prospective cohort study was conducted between 2022 and 2023 with a 6-month follow-up period. Latin American asylum seekers living with HIV were recruited mainly from non-governmental organisations and received care at an HIV clinic in a public hospital in Madrid. ResultsWe included 631 asylum seekers. The primary countries of origin were Colombia (30%), Venezuela (30%) and Peru (18%). The median age was 32 years (interquartile range (IQR): 28–37), and 553 (88%) were cis men of which 94% were men who have sex with men. Upon their arrival, 49% (n = 309) lacked social support, and 74% (n = 464) faced barriers when attempting to access the healthcare system. Upon entry in Europe, 500 (77%) participants were taking antiretroviral therapy (ART). At their first evaluation at the HIV clinic, only 386 (61%) had continued taking ART and 33% (n = 209) had detectable plasma HIV-1 RNA levels. Six months later, 99% took ART and 98% had achieved an undetectable viral load. ConclusionsLatin American asylum seekers living with HIV in Madrid, Spain encountered barriers to healthcare and to ART. One-third of these individuals presented detectable HIV viral load when assessed in the HIV clinic, highlighting this as an important public health issue.
Læs mereMedscape Infectious Diseases, 19.07.2024
Tilføjet 19.07.2024
Medscape Infectious Diseases, 5.07.2024
Tilføjet 5.07.2024
Patients at a high risk for HIV infection who received preexposure prophylactic injections with lenacapavir had 100% efficacy in a phase 3 clinical trial. Medscape Medical News
Læs mereMorbidity and Mortality Weekly Report (MMWR), 21.06.2024
Tilføjet 21.06.2024
This report describes a CDC-funded program that delivered approximately 440,000 HIV self-tests to U.S. residents.
Læs mere